This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Aug;11(8):709-11.

doi: 10.1016/S1470-2045(10)70128-5.

Molecularly targeted therapy: when to stop and when to continue?

Fred R Hirsch, Tony S Mok, Virginia Borges, Paul A Bunn Jr

PMID: 20570560
DOI: 10.1016/S1470-2045(10)70128-5

Molecularly targeted therapy: when to stop and when to continue?

Fred R Hirsch et al. Lancet Oncol. 2010 Aug.

. 2010 Aug;11(8):709-11.

doi: 10.1016/S1470-2045(10)70128-5.

Authors

Fred R Hirsch, Tony S Mok, Virginia Borges, Paul A Bunn Jr

PMID: 20570560
DOI: 10.1016/S1470-2045(10)70128-5

No abstract available

PubMed Disclaimer

Similar articles

Foreword.
Chen HX, Cleck JN, Coelho R, Dancey JE. Chen HX, et al. Curr Probl Cancer. 2009 Jul-Aug;33(4):244. doi: 10.1016/j.currproblcancer.2009.10.001. Curr Probl Cancer. 2009. PMID: 20082841 No abstract available.
Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Campos SM. Campos SM. Cancer Invest. 2008 Oct;26(8):757-68. doi: 10.1080/07357900801971040. Cancer Invest. 2008. PMID: 18853311 Review. No abstract available.
[Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Wang Y, Xu JM, Song ST. Wang Y, et al. Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):573-6. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 16438862 Chinese. No abstract available.
Review: side effects of approved molecular targeted therapies in solid cancers.
Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Widakowich C, et al. Oncologist. 2007 Dec;12(12):1443-55. doi: 10.1634/theoncologist.12-12-1443. Oncologist. 2007. PMID: 18165622 Review.
The HER3/ErbB3 receptor: a promising target in cancer drug therapy.
Desbois-Mouthon C. Desbois-Mouthon C. Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):255-9. doi: 10.1016/j.gcb.2010.03.002. Epub 2010 Apr 24. Gastroenterol Clin Biol. 2010. PMID: 20418034 No abstract available.

See all similar articles

Cited by

Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D. Torres KE, et al. Clin Cancer Res. 2011 Jun 15;17(12):3943-55. doi: 10.1158/1078-0432.CCR-11-0193. Epub 2011 May 3. Clin Cancer Res. 2011. PMID: 21540237 Free PMC article.
Withdrawal of anticancer therapy in advanced disease: a systematic literature review.
Clarke G, Johnston S, Corrie P, Kuhn I, Barclay S. Clarke G, et al. BMC Cancer. 2015 Nov 11;15:892. doi: 10.1186/s12885-015-1862-0. BMC Cancer. 2015. PMID: 26559912 Free PMC article.
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts.
Kang H, Lee HY, Lee KS, Kim JH. Kang H, et al. Korean J Radiol. 2012 Jul-Aug;13(4):371-90. doi: 10.3348/kjr.2012.13.4.371. Epub 2012 Jun 18. Korean J Radiol. 2012. PMID: 22778559 Free PMC article. Review.
Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis.
Kesselheim JC, Norden AD, Wen PY, Joffe S. Kesselheim JC, et al. Oncologist. 2011;16(10):1435-9. doi: 10.1634/theoncologist.2011-0047. Epub 2011 Sep 23. Oncologist. 2011. PMID: 21948651 Free PMC article.
A retroperitoneal NF1-independent malignant peripheral nerve sheath tumor with elevated serum CA125: case report and discussion.
Yan B, Meng X, Shi B, Shi J, Qin Z, Wei P. Yan B, et al. J Neurooncol. 2012 Aug;109(1):205-11. doi: 10.1007/s11060-012-0865-9. Epub 2012 Apr 19. J Neurooncol. 2012. PMID: 22528792

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal